文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

与慢性阻塞性肺疾病相关的肺外合并症:综述。

Extrapulmonary Comorbidities Associated with Chronic Obstructive Pulmonary Disease: A Review.

机构信息

School of Medical and Life Science, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610000, People's Republic of China.

Department of Respiratory and Critical Care Medicine, Suining Central Hospital, Suining, Sichuan, 629000, People's Republic of China.

出版信息

Int J Chron Obstruct Pulmon Dis. 2024 Feb 29;19:567-578. doi: 10.2147/COPD.S447739. eCollection 2024.


DOI:10.2147/COPD.S447739
PMID:38476124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10927883/
Abstract

Most patients with chronic obstructive pulmonary disease (COPD) suffer from at least one additional, clinically relevant chronic disease. To a degree, the high global prevalence and mortality rate of COPD is closely related to its extrapulmonary effects. Moreover, the various of comorbidities of COPD and itself interact with each other, resulting in diverse clinical manifestations and individual differences, and thus further influencing the prognosis as well as healthcare burden of COPD patients. This is closely related to the common risk factors of chronic diseases (aging, smoking, inactivity, etc.). Additionally, some pathophysiological mechanisms caused by COPD, including the systemic inflammatory response, hypoxia, oxidative stress, and others, also have an impact on other systems. But comprehensive management and medical interventions have not yet been established. The clinicians should improve their knowledge and skills in diagnosing as well as treating the comorbidities of COPD, and then aim to develop more individualized, efficient diagnostic and therapeutic strategies for different patients to achieve greater clinical benefits. In this article, we will review the risk factors, mechanisms, and treatment strategies for extrapulmonary comorbidities in chronic obstructive pulmonary disease, including cardiovascular diseases, diabetes, anemia, osteoporosis, emotional disorders, and gastroesophageal reflux disease.

摘要

大多数慢性阻塞性肺疾病(COPD)患者至少患有一种其他临床相关的慢性病。在某种程度上,COPD 的高全球患病率和死亡率与其肺外效应密切相关。此外,COPD 和自身的各种合并症相互作用,导致不同的临床表现和个体差异,从而进一步影响 COPD 患者的预后和医疗负担。这与慢性疾病的常见危险因素(衰老、吸烟、不活动等)密切相关。此外,COPD 引起的一些病理生理机制,包括全身炎症反应、缺氧、氧化应激等,也会对其他系统产生影响。但尚未建立全面的管理和医疗干预措施。临床医生应提高对 COPD 合并症的诊断和治疗的认识和技能,然后努力为不同患者制定更个体化、有效的诊断和治疗策略,以实现更大的临床获益。本文将综述慢性阻塞性肺疾病肺外合并症的危险因素、发病机制和治疗策略,包括心血管疾病、糖尿病、贫血、骨质疏松症、情绪障碍和胃食管反流病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e630/10927883/835a5cb44965/COPD-19-567-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e630/10927883/835a5cb44965/COPD-19-567-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e630/10927883/835a5cb44965/COPD-19-567-g0001.jpg

相似文献

[1]
Extrapulmonary Comorbidities Associated with Chronic Obstructive Pulmonary Disease: A Review.

Int J Chron Obstruct Pulmon Dis. 2024

[2]
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.

Respir Res. 2024-12-21

[3]
Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.

Cochrane Database Syst Rev. 2017-8-4

[4]
Self-management interventions for people with chronic obstructive pulmonary disease.

Cochrane Database Syst Rev. 2022-1-10

[5]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2020-1-9

[6]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2021-4-19

[7]
Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease.

Cochrane Database Syst Rev. 2017-5-23

[8]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2017-12-22

[9]
The Black Book of Psychotropic Dosing and Monitoring.

Psychopharmacol Bull. 2024-7-8

[10]
Vitamin D for the management of chronic obstructive pulmonary disease.

Cochrane Database Syst Rev. 2024-9-27

引用本文的文献

[1]
The Lung-Brain Axis in Chronic Obstructive Pulmonary Disease-Associated Neurocognitive Dysfunction: Mechanistic Insights and Potential Therapeutic Options.

Int J Biol Sci. 2025-5-15

[2]
Exercise Dysfunction and Pulmonary Rehabilitation Strategies in COPD Patients at High-Altitudes: A Review.

Int J Chron Obstruct Pulmon Dis. 2025-6-5

[3]
Prevalence of chronic respiratory disease using case-finding tools in adults living with noncommunicable disease in low- and middle-income countries: a systematic review.

BMC Pulm Med. 2025-5-10

[4]
Maximal Forced Inspiratory Flow Dynamics and Acute Exacerbation in Chronic Obstructive Pulmonary Disease Patients with Exacerbation History.

Tuberc Respir Dis (Seoul). 2025-7

[5]
Unmasking Cardiovascular Risk in Patients with COPD at Primary Care Settings: The Critical Role of Age, Sex, and Smoking.

J Clin Med. 2025-2-21

[6]
Carbon Monoxide Poisoning: Diagnosis, Prognostic Factors, Treatment Strategies, and Future Perspectives.

Diagnostics (Basel). 2025-2-27

[7]
The Role of Trace Elements in COPD: Pathogenetic Mechanisms and Therapeutic Potential of Zinc, Iron, Magnesium, Selenium, Manganese, Copper, and Calcium.

Nutrients. 2024-11-28

[8]
Artificial Intelligence in Chronic Obstructive Pulmonary Disease: Research Status, Trends, and Future Directions --A Bibliometric Analysis from 2009 to 2023.

Int J Chron Obstruct Pulmon Dis. 2024

[9]
HTR2B as a novel biomarker of chronic obstructive pulmonary disease with lung squamous cell carcinoma.

Sci Rep. 2024-6-8

本文引用的文献

[1]
Diabetic microvascular disease in non-classical beds: the hidden impact beyond the retina, the kidney, and the peripheral nerves.

Cardiovasc Diabetol. 2023-11-15

[2]
Non-apoptotic programmed cell deaths in diabetic pulmonary dysfunction: the new side of advanced glycation end products.

Front Endocrinol (Lausanne). 2023

[3]
The effect of iron therapy on oxidative stress and intestinal microbiota in inflammatory bowel diseases: A review on the conundrum.

Redox Biol. 2023-12

[4]
COPD and multimorbidity: recognising and addressing a syndemic occurrence.

Lancet Respir Med. 2023-11

[5]
Relationship between serum Th1/Th2 imbalance and depression in elderly patients with COPD and its clinical implications.

Technol Health Care. 2023

[6]
Tailored psychological intervention for anxiety or depression in COPD (TANDEM): a randomised controlled trial.

Eur Respir J. 2023-11

[7]
Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013-2023).

Molecules. 2023-7-21

[8]
Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.

J Orthop Surg Res. 2023-6-22

[9]
Effects of gastroesophageal reflux disease treatment with proton pump inhibitors on the risk of acute exacerbation and pneumonia in patients with COPD.

Respir Res. 2023-3-11

[10]
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.

Am J Respir Crit Care Med. 2023-4-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索